|
RICHMOND, VA – April 15, 2019 – The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it is accepting applications/letters of intent (LOIs) for round ten of grants to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.
Virginia Catalyst awards these funds to help accelerate translational research and the commercialization of Virginia’s innovations. The awards, which range from $200,000 to $800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:
Letters of intent (LOI) must be received by July 10, 2019 at 5:00 PM EDT. Projects that meet criteria will be invited to submit a full application by August 28, 2019. Read the full press release here CLICK HERE for more information and how to submit a Letter of Intent for Grant Round 10
0 Comments
RICHMOND, VA – January 15, 2019 – The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it is hosting a luncheon, in conjunction with Virginia Bio and CIT, featuring the National Institute on Drug Abuse (NIDA), Small Business Innovation Research (SBIR) program, and Deloitte Consulting. As part of the event, scheduled for January 23 from 11:30am-1:00pm, NIDA's Victor Prikhodko, Business Advisor to the Office of Translational Initiatives and Program Innovations (OTIPI), will discuss NIDA SBIR’s funding opportunities, including the recently released “HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis” RFA, and present some best practices for strong applications. In addition, Jon Baba, a Principal in Deloitte’s Global Public Sector Practice, will discuss Deloitte’s findings and strategic recommendations for neuroscience and addiction in the Commonwealth of Virginia. The Virginia Catalyst recently engaged Deloitte Consulting to explore and validate Virginia’s unmet addiction needs and benchmark Virginia’s competitive strengths and resources, and this presentation will unveil those findings.
Read the full press release here CLICK HERE to register for this free event CLICK HERE to view this event as it is live streamed (this event will not be recorded) In addition to these presentations on January 23rd: the Virginia Catalyst is providing a unique opportunity to have a 1:1 meeting with Victor Prikhodko from NIDA! Mr. Prikhodko will be available for 30-minute one-on-one meetings to discuss NIDA’s SBIR funding opportunities and to provide your company specific advice on best practices for strong applications and how to enhance your opportunity to receive funding. Meetings are scheduled on a first-come, first-serve basis! To schedule a 1:1 meeting contact: Suzänne Taylor [email protected] 804.937.3919 RICHMOND, VA – August 14, 2018 – The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it is accepting applications/letters of intent (LOIs) for round nine of grants to fund the development and commercialization of life science projects that address major unmet needs for improving human health. The awards, which range from $200,000 to $800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:
Read the full press release here CLICK HERE for more information and how to submit a Letter of Intent for Grant Round 9 Six winning projects to address human health needs such as myocardial infarctions, traumatic brain injury, musculoskeletal injury and catheter associated infections
The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it has awarded a total of $2.7 million to six life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with nearly $5.7 million in matching funds from partner companies, were awarded as Round 8 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet medical needs, and that can create high-paying jobs in the Commonwealth. “With this eighth round of funding, Virginia Catalyst has now awarded $15.7 million to Virginia companies and universities working on incredible technologies that can benefit the whole of society,” said Mike Grisham, CEO of Virginia Catalyst. “These six projects embody Virginia Catalyst’s core mission in that not only can they help citizens in our state, and our country, treat diseases and to discover new forms of treatment, but they can also help keep Virginia’s economy moving forward.” Read the full press release here. The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $500,000 grant to a collaborative bioscience commercialization project including a team from the Virginia Tech Carilion Research Institute, the University of Virginia, Carilion Medical Center, and BRAINBox Solutions, Inc., which is headquartered in Richmond. This grant, which includes matching funding of $500,000 provided by BRAINBox, will support the Virginia Brain Injury Diagnosis and Monitoring Initiative. This work will focus on a multi-modality system approach which will include point-of-care device detection of testing for brain injury blood biomarkers and development of integrated neuro-imaging, behavioral and biomarker models for outcome prediction for athletic brain injury and general brain injury management.
Read the full press release here. The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $400,000 grant to a collaborative bioscience commercialization project including a team from Virginia Commonwealth University, Eastern Virginia Medical School and ReAlta Life Sciences, LLC. This grant, which includes matching funding of $400,000 provided by ReAlta, is intended to establish the efficacy of Peptide Inhibitor of Complement C1 (PIC1) in decreasing brain injury in an animal model of neonatal Hypoxic-Ischemic Encephalopathy (HIE), as well as establish the long-term improvement in neurological outcomes after PIC1 treatment in an animal model of neonatal HIE.
Read the full press release here. The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it is accepting applications/letters of intent (LOIs) for round eight of grants to fund the development and commercialization of life science projects that address major unmet needs for improving human health. The awards, which range from $200,000 to $800,000, will accelerate translational research in the Commonwealth of Virginia through collaborations between industry and Virginia research universities. The purpose of this funding is to:
Letters of intent must be received by February 1, 2018 at 5:00 PM EST. Projects that meet criteria will be invited to submit a full application. Awards will be announced in April 2018. Read the full press release here. The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $500,000 grant to a collaborative bioscience commercialization project including a team from Virginia Commonwealth University, Virginia Tech, Inova Health System and Indivior Inc., a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy. This grant, which includes matching funding of $500,000 provided by Indivior, is intended to catalyze the development and commercialization of life science projects that address major unmet needs for improving human health, while also contributing to Virginia’s economic growth. This project is focused on addressing neuroscience initiatives involving the treatment and care of patients recovering from an opioid overdose.
Read the full press release. Read the full article at Virginia Business.
Virginia Biosciences Health Research Corporation, now known as Virginia Catalyst, and the Commonwealth Health Research Board (CHRB) have partnered to award a $300,000 grant to a team from Sanyal Biotechnology, Eastern Virginia Medical School and George Mason University.
The grant aims to help accelerate the commercialization of Sanyal Biotechnology’s innovative DIAMONDTM mouse model, which is being commercialized for preclinical assessment of therapeutic agents for non-alcoholic steatohepatitis (NASH), a severe liver disease that can lead to fibrosis, cirrhosis and liver cancer. Virginia Catalyst will provide $100,000 in funding while CHRB will provide $200,000. Sanyal Biotechnology is investing $166,000 as matching funds for the project titled, “Characterization of GUT Microbiome and Liver Cell Populations to Accelerate Commercialization of the DIAMONDTM Mouse Model.” |
RSS Feed
